CCL2 and pancreatic neoplasm: Research has shown that pancreatic cancer cells recruit and reprogram macrophages through the CCL2/CCR2 signaling pathway, leading to the subsequent release of TWEAK via the CCL5/TRAF6/NF-κB pathway.